Compare Amphastar Pharmaceuticals Inc (AMPH) vs PepsiCo, Inc. (PEP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs PepsiCo, Inc. — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while PepsiCo, Inc. trades at $138.21 (market cap $187.99B). The key difference: PepsiCo, Inc. is far larger — about 217.6× Amphastar Pharmaceuticals Inc's market cap, and PepsiCo, Inc. pays a 4.3% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | PEP | |
|---|---|---|
Market Cap | $863.95M | $187.99B |
Sector | Health | Consumer Staples |
52-Week High | $30.81 | $170.44 |
52-Week Low | $16.87 | $134.95 |
Enterprise Value | $1.26B | $230.48B |
Dividend Yield | — | 4.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
PepsiCo (PEP) trades at $137.69, down 0.95% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported revenue of $93.93 billion in 2025, with a net income margin of 10.78%, and has beaten EPS estimates in recent quarters. Recent news highlights price cuts on snacks like Doritos to address consumer pushback, while analysts anticipate Q1 2026 results.
The outlook is mixed: strong profitability and dividend yield near 4% support value, but price sensitivity and competitive pressures pose risks. Analyst consensus is a 'Hold' with a $158.79 price target, suggesting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →
